Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

253.97
+0.11000.04%
Volume:303.70K
Turnover:77.49M
Market Cap:16.66B
PE:29.37
High:258.58
Open:255.56
Low:253.45
Close:253.86
52wk High:282.15
52wk Low:160.86
Shares:65.59M
Float Shares:63.84M
Volume Ratio:0.70
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.65
EPS(LYR):-4.4176
ROE:332.65%
ROA:-0.60%
PB:30.02
PE(LYR):-57.49

Loading ...

Ascendis Pharma is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 24

Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong

Simply Wall St.
·
Jul 12

Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says

MT Newswires Live
·
Jul 09

Wedbush Raises Price Target on Ascendis Pharma to $327 From $273, Keeps Outperform Rating

MT Newswires Live
·
Jul 09

Ascendis Pharma A/s : Wedbush Raises Target Price to $327 from $273

THOMSON REUTERS
·
Jul 09

Ascendis Pharma Releases Week 104 Approach Trial Radiographic Data Presentation on Transcon CNP in Achondroplasia

Reuters
·
Jul 09

European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading

MT Newswires Live
·
Jul 08

Barclays Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
Jul 08

Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data

Simply Wall St.
·
Jul 04

14 Value Stocks of Companies Primed for Rapid Growth Through 2028

Dow Jones
·
Jul 02

Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial

TIPRANKS
·
Jun 30

Ascendis Says Transcon CNP Achondroplasia Trial Shows Continued Leg-alignment Gains at Week 104

Reuters
·
Jun 30

Ascendis Pharma Added to Multiple Russell Indexes

MT Newswires Live
·
Jun 27

Ascendis Pharma Reports Week 104 Approach Trial Data Showing Improved Leg Alignment with Transcon CNP in Achondroplasia

Reuters
·
Jun 26

Movement Alert|Ascendis Pharma Rises 8.3% in Regular Trading, Core Drug Long-Term Clinical Data Impresses as Analysts Reiterate Bullish Stance

Market Focus
·
Jun 26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Jun 18

Ascendis Pharma sells priority review voucher for $187.5 million cash

Reuters
·
Jun 18

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Jun 17

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

TIPRANKS
·
Jun 16

Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says

MT Newswires Live
·
Jun 15